John R. Schroer serves as Chief Financial Officer, Treasurer of the Company. Mr. Schroer has served as our chief financial officer and treasurer since May 2018. From January 2014 to April 2018, Mr. Schroer served as a director and sector head – healthcare at Allianz Global Investors, a global asset management company. From 2009 to December 2013, he served as president and chief investment officer at Schroer Capital, LP, a financial services company that he founded. Mr. Schroer received a B.S. in history and international relations and an M.B.A. from the University of Wisconsin-Madison.
As the Chief Financial Officer e Treasurer of Telesis Bio Inc, the total compensation of John Schroer at Telesis Bio Inc is $1,197,500. There are 2 executives at Telesis Bio Inc getting paid more, with Ronald Renaud having the highest compensation of $3,386,150.
John Schroer is 54, he's been the Chief Financial Officer e Treasurer of Telesis Bio Inc since 2018. There are 7 older and 6 younger executives at Telesis Bio Inc. The oldest executive at Telesis Bio Inc is Jean-Francois Formela, 63, who is the Independent Director.
John's mailing address filed with the SEC is C/O TRANSLATE BIO, INC., 29 HARTWELL AVE, LEXINGTON, MA, 02421.
Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk, eHuman Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.
sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Telesis Bio Inc executives and other stock owners filed with the SEC include: